References
- Shigdar S, Luczo J, Wei MQ, Bell R, Danks A, Liu K, et al. Aptamer therapeutics: the 21st century’s magic bullet of nanomedicine. Open Conf Proc J 2010; 1: 118-24. 10.2174/22102892010010100118
- Baird GS. Where are all the aptamers? Am J Clin Pathol 2010; 134: 529-31. 10.1309/AJCPFU4CG2WGJJKS
- Šmuc T, Ahn IY, Ulrich H. Nucleic acid aptamers as high affinity ligands in biotechnology and biosensorics. J Pharm Biomed Anal 2013; 81-82: 210-7. 10.1016/j.jpba.2013.03.014
- Zhou J, Rossi JJ. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 2011; 21: 1-10. 10.1089/oli.2010.0264
- Ulrich H, Wrenger C. Disease-specific biomarker discovery by aptamers. Cytometry A 2009; 75: 727-33. 10.1002/cyto.a.20766
- Nery AA, Wrenger C, Ulrich H. Recognition of biomarkers and cell-specific molecular signatures: aptamers as capture agents. J Sep Sci 2009; 32: 1523-30. 10.1002/jssc.200800695
- Ni S, Yao H, Wang L, Lu J, Jiang F, Lu A, et al. Chemical modifications of nucleic acid aptamers for therapeutic purposes. Int J Mol Sci 2017; pii: E1683. 10.3390/ijms18081683.
- Ulrich H, Tárnok A. Flow cytometry detection of circulating tumor cells: achievements and limitations as prognostic parameters. Cytometry A 2014; 85: 201-2. 10.1002/cyto.a.22441
- Krebs MG, Hou J-M, Sloane R, Lancashire L, Priest L, Nonaka D, et al. Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. J Thorac Oncol [Internet]. 2012; 7: 306-15.
- Zhao Z, Xu L, Shi X, Tan W, Shangguan D. Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. Analyst 2009; 134: 1808-14. 10.1039/B904476K
- Jimenez E, Sefah K, Lopez-Colon D, Van Simaeys D, Chen HWi, Tockman MS, et al. Generation of lung adenocarcinoma DNA aptamers for cancer studies. PLoS One 2012; 7: 1-7. 10.1371/journal.pone.0046222
- Zamay GS, Kolovskaya OS, Zamay TN, Glazyrin YE, Krat AV, Zubkova O, et al. Aptamers selected to postoperative lung adenocarcinoma detect circulating tumor cells in human blood. Mol Ther 2015; 23: 1486-96. 10.1038/mt.2015.108
- Wang P, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, et al. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PLoS One 2013; 8: e57020. 10.1371/journal.pone.0057020
- Yan X, Luo H, Zhou X, Zhu B, Wang Y, Bian X. Identification of CD90 as a marker for lung cancer stem cells in A549 and H446 cell lines. Oncol Rep 2013; 30: 2733-40. 10.3892/or.2013.2784
- Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A.; 100: 15416-21. 10.1073/pnas.2136683100
- Giordano RJ, Cardó-Vila M, Lahdenranta J, Pasqualini R, Arap W. Biopanning and rapid analysis of selective interactive ligands. Nat Med 2001; 7: 1249-53. 10.1038/nm1101-1249
- Telez A, Rubinstein P. Rapid method for separation of blood cells. Transfusion 1970; 10: 223-5. 10.1111/j.1537-2995.1970.tb00733
- Nascimento IC, Nery AA, Bassaneze V, Krieger JE, Ulrich H. Applications of aptamers in flow and imaging cytometry. Methods Mol Biol 2016; 1380: 127-34. 10.1007/978-1-4939-3197-2_10
- Bailey TL, Johnson J, Grant CE, Noble WS. The MEME suite. Nucleic Acids Res 2015; 43: W39-49. 10.1093/nar/gkv416
- Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 2013; 30: 2725-9. 10.1093/molbev/mst197
- Markham NR, Zuker M. UNAFold: Software for nucleic acid folding and hybridization. Methods Mol Biol 2008; 453: 3-31. 10.1007/978-1-60327-429-6_1
- Kinghorn AB, Fraser LA, Tanner JA. Aptamer bioinformatics. Int J Mol Sci 2017; pii: E2561. 10.3390/ijms18122516
- Berghmans T, Pasleau F, Paesmans M, Bonduelle Y, Cadranel J, Toth IC, et al. Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. Eur Respir J 2012; 39: 9-28. 10.1183/09031936.00190310
- Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: standardization for use in the clinical trial setting. J Clin Oncol 2008; 26: 983-94. 10.1200/JCO.2007.12.9858